A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 71
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : ICPI
Long Form : immune checkpoint inhibitors
No. Year Title Co-occurring Abbreviation
2021 Autoimmune Encephalitis Related to Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review. ---
2021 CD4 T Cell-Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair-Deficient Tumors. B2M, MMRd
2021 Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma. HCC, PD-L1
2021 Concomitant Proton Pump Inhibitors and Immune Checkpoint Inhibitors Increase Nephritis Frequency. PPI
2021 Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report. BRAFi, NGS, NSCLC, PD-L1, PFS
2021 Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. CGP, NC, pMHC
2021 Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade. DCs, TME
2021 Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. irAEs
2021 Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors. DDR
10  2021 Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression. CGP, CN, SCC
11  2021 Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC). HLRCC, NCCN, TKI
12  2021 Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis. AChR, irAEs, IVIG, MG
13  2021 The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries. CTLA-4, PD
14  2021 The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer. irAEs
15  2021 Thyroid disorders associated with immune control point inhibitors. TD
16  2021 Vaginal mucositis related to immunotherapy in endometrial cancer. USC
17  2020 A Case of Immune Checkpoint Inhibitor Refractory Colitis Treated with Mycophenolate and High-dose Steroids. ---
18  2020 Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. DCR, HR, mSMI, NSCLC, OS, PFS
19  2020 Can Ipilimumab restore immune response in advanced NSCLC after progression on anti-PD-1/PD-L1 agents? DCR, irAE, NSCLC, ORR, OS, PR, SD
20  2020 Central nervous system injury from novel cancer immunotherapies. CAR-T, CNS, irAE
21  2020 Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses Against Hepatocellular Carcinoma. CIRP, GPC3-CIRP, HCC, OVA-CIRP
22  2020 Combining immune checkpoint inhibitors with denosumab: a new era in repurposing denosumab in oncology? CTLA-4, PD, RANKL
23  2020 Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma. DEGs, SAM
24  2020 Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. CGP, dMMR, GEP, IHC, MSI, TILs, TMB
25  2020 Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives. cHL, DLBCL, EBV, GZL, NHL, ORR, PCNSL, PMBL, PTL
26  2020 Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients. NSCLC, OS, PD-1, PD-L1, PFS
27  2020 Immunotherapy induced enterocolitis and gastritis - What to do and when? ---
28  2020 Management of the Adverse Effects of Immune Checkpoint Inhibitors. irAEs
29  2020 Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature. irAEs
30  2020 Pembrolizumab-Induced Ocular Myasthenic Crisis. AChR, CD, IVIG, OMG
31  2020 Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer. CGP, GAs, MBCs, MSI, TMB, TNBC
32  2020 Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. AST, GGT, HR, irAE, irGGT, OR, OS
33  2020 Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors. GBM, TAM
34  2020 Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event. CT, PAI
35  2020 Telomerase and CD4 T Cell Immunity in Cancer. TERT
36  2020 The role of T cell trafficking in CTLA-4blockade-induced gut immunopathology. CTLA-4, DSS, irAEs, LP
37  2020 Ulcerative colitis exacerbation after the onset of immune checkpoint inhibitor related colitis. CD, IBD, IMC, irAEs, UC
38  2020 [HIV and cancer: Update 2020]. cART, PLWH
39  2019 Antibiotic therapy and outcome from immune-checkpoint inhibitors. ---
40  2019 Can an amino acid-based oral rehydration solution be effective in managing immune therapy-induced diarrhea? AA-ORS, irAEs, ITID
41  2019 Hepatotoxicity of immune check point inhibitors: Approach and management. AEs, HCC
42  2019 Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines? ALC
43  2019 Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database. AEs, GBS, JADER, MG, PD-L1, ROR
44  2019 Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. CAR-T, irAEs
45  2019 Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results. MKP, MSD, MUP
46  2019 Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. PDAC, scRNA-seq, TME
47  2019 Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. ICPIs, Mb, TMB
48  2019 [Gastrointestinal complications of the new immune checkpoint inhibitor therapies]. ---
49  2019 [Immunotherapy-induced endocrinopathies: Insights from the 2018 French Endocrine Society Guidelines]. ---
50  2018 BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. CI, PD-L1, PFS, TMB
51  2018 Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity? MC
52  2018 Drug-induced xenogenization of tumors: A possible role in the immune control of malignant cell growth in the brain? DIX, ITH, MGMT, TZC
53  2018 Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency. CMMRD, GBM, MLH1, MSH2, MSH6, PMS2
54  2018 Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. ---
55  2018 Immune checkpoint inhibitors and radiotherapy-concept and review of current literature. ---
56  2018 Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. IDC
57  2018 Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. ---
58  2018 Neuromuscular complications of immune checkpoint inhibitor therapy. ---
59  2018 Review of Immune Therapies Targeting Ovarian Cancer. ---
60  2018 The evolving immunotherapeutic landscape in advanced oesophagogastric cancer. OG
61  2018 The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective. AEsTC, C/LYG, DOC, Gr, NIVO, NSCLC, OS, PD-L1
62  2018 [Immune Checkpoint Induced Colitis]. ---
63  2018 [Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment]. IFN-gamma, IL-17
64  2017 Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research. BRCA, MSI, PD-L1, TILs
65  2017 Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. ---
66  2017 Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. ---
67  2017 PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry. CGP, CRC, IC, IHC, MMR-P, MMRd, NSCLC, TC
68  2017 Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. CX, DIX
69  2017 Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. irAEs
70  2016 Management of toxicities of immune checkpoint inhibitors. irAEs
71  2016 Renal effects of immune checkpoint inhibitors. CTLA-4